| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Richard D Carr, Marianne O Larsen, Maria Sörhede Winzell, Katarina Jelic, Ola Lindgren, Carolyn F Deacon, Bo Ahré. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. American journal of physiology. Endocrinology and metabolism. vol 295. issue 4. 2008-11-17. PMID:18612044. |
after protein, the early gip, but not glp-1, responses correlated to insulin (r(2)=0.86; p=0.0001) but not glucagon responses. |
2008-11-17 |
2023-08-12 |
Not clear |
| Golnaz Madadi, Prasad S Dalvi, Denise D Belsha. Regulation of brain insulin mRNA by glucose and glucagon-like peptide 1. Biochemical and biophysical research communications. vol 376. issue 4. 2008-11-13. PMID:18809381. |
the insulin cis-regulatory regions differ between the pancreas and the hypothalamus, and glucose and glp-1 regulate the expression of hypothalamic insulin. |
2008-11-13 |
2023-08-12 |
mouse |
| D Raddatz, W Nolte, C Rossbach, U Leonhardt, A Buchwald, K H Scholz, G Ramador. Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 116. issue 8. 2008-11-05. PMID:18770489. |
diabetes in liver cirrhosis is associated with a blunted insulin response, which might be explained by an impaired release of the incretin hormone glucagon-like peptide 1 (glp-1) into the portal circulation. |
2008-11-05 |
2023-08-12 |
Not clear |
| Claude Knauf, Patrice D Cani, Afifa Ait-Belgnaoui, Alexandre Benani, Cédric Dray, Cendrine Cabou, André Colom, Marc Uldry, Sophie Rastrelli, Eric Sabatier, Natacha Godet, Aurélie Waget, Luc Pénicaud, Philippe Valet, Rémy Burceli. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology. vol 149. issue 10. 2008-11-04. PMID:18556349. |
we previously demonstrated that brain glp-1 increases glucose-dependent hyperinsulinemia and insulin resistance. |
2008-11-04 |
2023-08-12 |
mouse |
| Claude Knauf, Patrice D Cani, Afifa Ait-Belgnaoui, Alexandre Benani, Cédric Dray, Cendrine Cabou, André Colom, Marc Uldry, Sophie Rastrelli, Eric Sabatier, Natacha Godet, Aurélie Waget, Luc Pénicaud, Philippe Valet, Rémy Burceli. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology. vol 149. issue 10. 2008-11-04. PMID:18556349. |
our data show that a 1-month chronic blockage of brain glp-1 signaling by exendin-9 (ex9), totally prevented hyperinsulinemia and insulin resistance in hfd mice. |
2008-11-04 |
2023-08-12 |
mouse |
| Claude Knauf, Patrice D Cani, Afifa Ait-Belgnaoui, Alexandre Benani, Cédric Dray, Cendrine Cabou, André Colom, Marc Uldry, Sophie Rastrelli, Eric Sabatier, Natacha Godet, Aurélie Waget, Luc Pénicaud, Philippe Valet, Rémy Burceli. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology. vol 149. issue 10. 2008-11-04. PMID:18556349. |
thus, we have demonstrated that in response to a hfd, brain glp-1 signaling induces hyperinsulinemia and insulin resistance and decreases energy expenditure by reducing metabolic thermogenesis and ambulatory activity. |
2008-11-04 |
2023-08-12 |
mouse |
| Kevin B Moore, Christopher D Saude. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. American journal of therapeutics. vol 15. issue 5. 2008-11-04. PMID:18806525. |
through the action of glp-1 and gip, dpp-iv inhibitors improve preprandial and postprandial glucose by enhancing insulin secretion and reducing postprandial concentrations of glucagon. |
2008-11-04 |
2023-08-12 |
Not clear |
| Merewyn K Loder, Gabriela da Silva Xavier, Angela McDonald, Guy A Rutte. TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochemical Society transactions. vol 36. issue Pt 3. 2008-11-03. PMID:18481957. |
the risk alleles have been associated with reduced glucose and glp-1 (glucagon-like peptide 1)-stimulated insulin secretion. |
2008-11-03 |
2023-08-12 |
human |
| Subhas C Biswas, Jean Buteau, Lloyd A Green. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochemical research. vol 33. issue 9. 2008-10-31. PMID:18351462. |
glucagon-like peptide-1 (glp-1) is a glucoincretin hormone most intensively studied for its actions on insulin secreting beta-cells. |
2008-10-31 |
2023-08-12 |
Not clear |
| Diva D De León, Changhong Li, Madeleine I Delson, Franz M Matschinsky, Charles A Stanley, Doris A Stoffer. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. The Journal of biological chemistry. vol 283. issue 38. 2008-10-27. PMID:18635551. |
these findings suggest that camp plays a key role in k(atp)-independent insulin secretion and that the glp-1 receptor is constitutively active in sur-1(-/-) beta-cells. |
2008-10-27 |
2023-08-12 |
mouse |
| Yuan Li, Changhong Shi, Qiujun Lv, Huming Zhang, Biehu Li, Guangxing Bian, Qingsheng Huang, Weihua Zhang, Xiaoping Xue, Xin Ren, Hua Gao, Chunyi Sun, Juan Wang, Mingjie Zhan. GLP-1 C-terminal structures affect its blood glucose lowering-function. Journal of peptide science : an official publication of the European Peptide Society. vol 14. issue 7. 2008-10-24. PMID:18200618. |
glucagon-like peptide-1 (glp-1), which is an endogenous insulinotropic peptide that can stimulate islet cells to secret insulin, is a promising new drug candidate for the treatment of type 2 diabetes. |
2008-10-24 |
2023-08-12 |
rat |
| Bumsup Lee, Lihong Shi, Daniel B Kassel, Tomoko Asakawa, Koji Takeuchi, Ronald J Christophe. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European journal of pharmacology. vol 589. issue 1-3. 2008-10-24. PMID:18538760. |
in zucker fa/fa rats, a single dose of alogliptin (0.3, 1, 3, and 10 mg/kg) inhibited plasma dpp-4 (91% to 100% at 2 h and 20% to 66% at 24 h), increased plasma glp-1 (2- to 3-fold increase in auc(0-20 min)) and increased early-phase insulin secretion (1.5- to 2.6-fold increase in auc(0-20 min)) and reduced blood glucose excursion (31%-67% decrease in auc(0-90 min)) after oral glucose challenge. |
2008-10-24 |
2023-08-12 |
human |
| Wilma L Suarez-Pinzon, Jonathan R T Lakey, Alex Rabinovitc. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell transplantation. vol 17. issue 6. 2008-10-15. PMID:18819251. |
immunocytochemical examination revealed a fourfold increase in insulin-positive cells in the human pancreatic cell grafts in glp-1 plus gastrin-treated mice, and most of this increase was accounted for by the appearance of cytokeratin 19-positive pancreatic duct cells expressing insulin. |
2008-10-15 |
2023-08-12 |
mouse |
| Keiko Tanaka-Amino, Kazumi Matsumoto, Yoshifumi Hatakeyama, Ichiro Shima, Shoji Takakura, Seitaro Mut. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity. European journal of pharmacology. vol 590. issue 1-3. 2008-10-14. PMID:18582861. |
a single oral administration of asp4,000 at doses of 0.03-1 mg/kg suppressed plasma dpp4 activity, and then reduced the glucose level with increasing the active glp-1 and insulin levels in oral glucose tolerance test. |
2008-10-14 |
2023-08-12 |
human |
| Yuka Someya, Atsuo Tahara, Ryosuke Nakano, Akiko Matsuyama-Yokono, Itsuro Nagase, Yasuhisa Fukunaga, Toshiyuki Takasu, Masahiko Hayakawa, Masayuki Shibasak. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's archives of pharmacology. vol 377. issue 3. 2008-09-30. PMID:18398600. |
this was accompanied by increases in the plasma active glp-1 and insulin levels. |
2008-09-30 |
2023-08-12 |
mouse |
| J R Strawn, D A D'Alessio, P E Keck, R J Seele. Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder. Journal of psychiatric research. vol 42. issue 9. 2008-09-26. PMID:17888452. |
the insulin secretogogue glucagon like peptide-1 (glp-1), as well as agents which enhance glp-1 signaling, are being studied as potential treatments for diabetes. |
2008-09-26 |
2023-08-12 |
human |
| Tianru Ji. Why diabetes patients are more prone to the development of colon cancer? Medical hypotheses. vol 71. issue 2. 2008-09-19. PMID:18456417. |
the intestinal endocrine l cells produce an incretin hormone, namely glucagon-like peptide-1 (glp-1), which stimulates insulin secretion in blood glucose dependent manner, pancreatic beta cell proliferation and neogenesis. |
2008-09-19 |
2023-08-12 |
Not clear |
| Tianru Ji. Why diabetes patients are more prone to the development of colon cancer? Medical hypotheses. vol 71. issue 2. 2008-09-19. PMID:18456417. |
i hypothesize that during the development of insulin resistance, intestinal endocrine l cells produce more glp-1 for compensation. |
2008-09-19 |
2023-08-12 |
Not clear |
| Luis Arnés, Nieves González, Pilar Tornero-Esteban, Verónica Sancho, Alicia Acitores, Isabel Valverde, Elena Delgado, María L Villanueva-Peñacarrill. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. International journal of molecular medicine. vol 22. issue 1. 2008-09-18. PMID:18575785. |
in normal rats, exendin-4, like glp-1 and insulin, enhanced glucose uptake. |
2008-09-18 |
2023-08-12 |
human |
| Luis Arnés, Nieves González, Pilar Tornero-Esteban, Verónica Sancho, Alicia Acitores, Isabel Valverde, Elena Delgado, María L Villanueva-Peñacarrill. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. International journal of molecular medicine. vol 22. issue 1. 2008-09-18. PMID:18575785. |
type 2 diabetic rats showed lower than normal basal muscle glucose transport and oxidation value, and higher glycogen synthase alpha activity and pyruvate release; however, no modification of glucose uptake by glp-1 or exendin-4 was detected, at variance with insulin, and basal activity of pi3k/pkb was lower than normal, while that of p70s6k and mapks was higher. |
2008-09-18 |
2023-08-12 |
human |